Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atomoxetine in the Prevention of Vasovagal Syncope (POST7)
NCT05159687Phase 3Recruiting
- Sponsor
- University of Calgary
- Start
- Jun 2022
- Primary completion
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of atomoxetine in vasovagal syncope (2 arms), sponsored by University of Calgary. Primary endpoint: Proportion of patients having at least one syncope recurrence at 12 months. Started Jun 2022; status: recruiting.
02
Drugs
atomoxetine
03
Conditions
vasovagal syncope
Beyond the preview
Go deeper on NCT05159687.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05159687.